Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Narendranath Epperla

Showing results (11-20 of 207) with videos related to

Pageof 21
Sort By:
Clinical Medicine & Research|March 27, 2014
Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasiaNarendranath Epperla, William Hocking
Current Hematologic Malignancy Reports|January 25, 2021
A New Target for Hodgkin Lymphoma - Camidanlumab TesirineNarendranath Epperla, Mehdi Hamadani
Hematology. American Society of Hematology. Education Program|December 10, 2021
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitorsNarendranath Epperla, Mehdi Hamadani
Springerplus|September 1, 2015
Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasoneNarendranath Epperla, Fergus McKiernan
Expert Review of Anticancer Therapy|April 7, 2022
Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approachTimothy J Voorhees, Narendranath Epperla
Journal of Palliative Medicine|June 3, 2016
Chemotherapy: Response and Survival Data #99Narendranath Epperla, David E Weissman
Journal of Hematology & Oncology|July 2, 2025
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapiesAllison M Bock, Narendranath Epperla
Skeletal Radiology|April 11, 2014
An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosisNarendranath Epperla, Fergus E McKiernan
Blood|April 23, 2021
How I incorporate novel agents into the treatment of classical Hodgkin lymphomaNarendranath Epperla, Alex F Herrera
Biomarker Research|September 27, 2023
Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort studyJohn L Vaughn, Narendranath Epperla
Pageof 21

Showing results (11-20 of 207) with videos related to

Sort By:
Pageof 21
Clinical Medicine & Research|March 27, 2014
Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasiaNarendranath Epperla, William Hocking
Current Hematologic Malignancy Reports|January 25, 2021
A New Target for Hodgkin Lymphoma - Camidanlumab TesirineNarendranath Epperla, Mehdi Hamadani
Hematology. American Society of Hematology. Education Program|December 10, 2021
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitorsNarendranath Epperla, Mehdi Hamadani
Springerplus|September 1, 2015
Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasoneNarendranath Epperla, Fergus McKiernan
Expert Review of Anticancer Therapy|April 7, 2022
Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approachTimothy J Voorhees, Narendranath Epperla
Journal of Palliative Medicine|June 3, 2016
Chemotherapy: Response and Survival Data #99Narendranath Epperla, David E Weissman
Journal of Hematology & Oncology|July 2, 2025
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapiesAllison M Bock, Narendranath Epperla
Skeletal Radiology|April 11, 2014
An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosisNarendranath Epperla, Fergus E McKiernan
Blood|April 23, 2021
How I incorporate novel agents into the treatment of classical Hodgkin lymphomaNarendranath Epperla, Alex F Herrera
Biomarker Research|September 27, 2023
Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort studyJohn L Vaughn, Narendranath Epperla
Pageof 21